90 results about "Mice brain" patented technology

The invention provides a compound probiotic for relieving anxiety behaviors and application of the compound probiotic. The compound probiotic comprises bifidobacterium animalis YRK-12 (the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.28597) and lactobacillus rhamnosus LRa-Y8 (the preservation number is CGMCC NO.34186). The invention finds that the two bacteria are compounded and can be matched and promoted with each other, and have a synergistic effect on the aspect of preventing and treating anxiety disorder, which is specifically shown as follows: the reduction of center lattice movement time and percentage caused by LPS (Lipopolysaccharide) is relieved; the increase of mouse serum proinflammatory cytokines caused by LPS is improved; the increase of mouse brain tissue proinflammatory cytokines caused by LPS is improved. Under the condition that the using amount of the bacteria is consistent, the effect of the compounding of the two bacteria on improving the anxiety-like behavior induced by the LPS is obviously improved. Meanwhile, the two bacteria are probiotics, so that the product is safe and is not easy to generate resistance.

The invention discloses application of a plant lactobacillus CCFM1357 to conversion of anthocyanin to generate various active metabolites, inhibition of a cGAS-STING pathway and enhancement of improvement of brain aging, and belongs to the technical field of microorganisms and the technical field of medicines. The phytobacterium plantarum CCFM1357 fermented anthocyanin and the compound preparation thereof provided by the invention have the following effects: (1) a marker for relieving D-gal induced mouse brain senescence and a marker for relieving D-gal induced mouse brain senescence; (2) promoting and relieving D-gal induced mouse histopathologic characterization; (3) relieving D-gal induced mouse neuroinflammation; (4) relieving behavioral characterization of the D-gal induced aging mouse; and (5) a cGAS-STING signal channel is inhibited. The phytobacterium plantarum CCFM1357 fermented anthocyanin and the compound preparation thereof provided by the invention can be used for a product for relieving brain aging, and have a huge application prospect.

The invention discloses application of eugenin in preparation of a medicine for treating cerebral arterial thrombosis, and belongs to the technical field of medicines. An in-vivo middle cerebral artery occlusion model is adopted, after reperfusion is conducted for 24 h, the cerebral infarction volume and movement coordination function defect of a mouse are detected to evaluate the treatment effect of eugenin, and activation of microglial cells and survival of neuronal cells are observed through immunofluorescence to clarify the action way of eugenin. Pharmacological activity shows that eugenin can obviously reduce the cerebral infarction volume of a model mouse, improve pathological damage of cells and promote recovery of a motion coordination function, and the action way of eugenin is to promote survival of neuronal cells and inhibit activation of microglial cells. Research results indicate that eugenin has the effect of resisting cerebral arterial thrombosis and can be used as a candidate medicine for developing the cerebral arterial thrombosis resisting medicine.

The invention discloses a method for detecting mouse brain nucleus activation based on manganese-enhanced magnetic resonance imaging, and belongs to the field of image processing, and the method comprises the steps: converting an acquired mouse head manganese-enhanced magnetic resonance image into an NIFTI format, and enabling the direction and voxel size of the image to be consistent with a standard mouse brain map template; performing offset field correction on the image; loading a PLKA-nnUNet model, carrying out image segmentation on the image, outputting a binary brain mask, and extracting an individual mouse brain image from the image after bias field correction; carrying out image registration and intensity normalization; for each registered individual mouse brain image, calculating relaxation rate mean values of four hippocampal subregions of the mouse brain R1 image, wherein the relaxation rate mean values are used for quantitatively comparing mouse brain activation conditions; and carrying out voxel-level statistical test on the registered and normalized individual mouse brain images to identify brain regions with intensity differences among different experimental conditions. According to the method, the dependence on professional operation is reduced.

The present invention relates to the field of biomedicine technology, and specifically discloses a dicyanoisophorone fluorescent probe for detecting brain β-amyloid protein, its preparation method and application. The fluorescent probe of the present invention is based on the dicyanoisophorone structure, and a probe with dual recognition sites is formed by introducing a carbamate group and an N,N-dimethylamino group. Compared with probes with a single recognition site, probes with dual recognition sites have a more sensitive fluorescent response to Aβ aggregates in vitro and show higher binding affinity and selectivity. The probe can effectively cross the blood-brain barrier and show high reactivity in the brains of Alzheimer's disease model mice. In addition, the probe can monitor the Aβ levels in the brains of Alzheimer's disease mice of different ages. It has great potential in the early diagnosis of neurodegenerative diseases.

The application discloses a photosensitizer targeting beta amyloid, and a preparation method and application thereof. The photosensitizer is a photosensitizer with A-D-A configuration, and a structural formula thereof is shown as formula I. The photosensitizer synthesized in the application has a longer emission wavelength, and after being combined with beta amyloid, the fluorescence signal is obviously enhanced, and can effectively generate singlet oxygen, that is, the photosensitizer can target mark A beta protein, and is used for fluorescence imaging of the A beta protein; and after the photosensitizer synthesized in the application is combined with beta amyloid in the brain of an Alzheimer's disease (AD) model mouse, the cognitive ability of the AD mouse can be effectively improved, A beta-mediated neurotoxicity can be reduced, and clearance of A beta plaques can be promoted, that is, the photosensitizer can be used for early diagnosis and treatment of Alzheimer's disease.

The invention relates to the technical field of biomedical engineering, in particular to an invasive mouse electroencephalogram data acquisition and analysis system and method. The system comprises a motion structure assembly used for providing a motion carrier for a mouse and collecting motion parameters; the control assembly is used for adjusting motor output according to the target parameter, generating a synchronous time label instruction, recording the actual motion parameter in real time and storing the actual motion parameter in association with the time label; and the data acquisition and analysis component is used for acquiring original electroencephalogram data, synchronously storing a time label, aligning an electroencephalogram sampling time sequence with a motion control time label sequence, extracting electroencephalogram pulse position information, calculating a neuron discharge frequency and establishing a correlation between the discharge frequency and a motion parameter. According to the technical scheme, accurate and synchronous acquisition, automatic alignment of time stamps and multi-dimensional correlation analysis of mouse motion states and electroencephalogram signals can be realized.

This invention discloses the application of burdock root polysaccharide in the preparation of drugs for treating cognitive impairment, belonging to the field of traditional Chinese medicine technology. Experiments demonstrate that burdock root polysaccharide can improve cognitive impairment and independent exploration ability in D-galactose-induced cognitive impairment model mice, increase superoxide dismutase activity in mouse serum, reduce malondialdehyde content, decrease the content of interleukin-1β and tumor necrosis factor-α in the hippocampus of mouse brains, and alleviate the loss of neurons in the hippocampus of cognitive impairment model mice, thereby achieving a neuroprotective effect and demonstrating a good therapeutic effect on cognitive impairment. This provides a new approach for developing drugs related to the treatment of cognitive impairment.

The invention belongs to the technical field of biology, and particularly relates to a construction method of a respiratory syncytial virus infected mouse model. Disodium clodronate liposome with the concentration of 4ng / mL is injected into the lateral ventricle of the mouse through stereotactic positioning of the brain. 48h after injection, mouse brain tissues are taken to detect the activation state of microglial cells through immunofluorescence and WB, after it is confirmed that the microglial cells are inhibited, RSV (virus titer: 2.8 * 10 < 6 > PFU) nasal drop infection experiments are carried out on the mouse, and after the 5th day after virus infection, the mouse is infected by the RSV (virus titer: 2.8 * 10 < 6 > PFU) nasal drop infection experiments. Likewise, mouse brain tissue is taken for virus load detection, and neuropathological changes of the mouse brain tissue are observed through HE staining, immunofluorescence and TUNEL staining, so that the method can be used for constructing a research model of RSV-related nervous system diseases.

This invention discloses a method for preparing NK cells, the NK cells obtained thereby, and their applications. The method includes: sorting NK cells from peripheral blood of an allogeneic donor; culturing them in a serum-free medium containing CD3 monoclonal antibody, CD16 antibody, and IL-2, without the need for a feeder layer; preferably, IL-21 is added for amplification on days 3-5 of culture, and the cells are cultured for 20-40 days. This method yields non-genetically modified NK cells, among which CD56... bright The NK cells comprise >90% of the cell line and highly express a variety of activating and functional molecules. These NK cells effectively clear Aβ oligomers and senescent cells, and alleviate neuroinflammation. In treatment, intracranial injection achieves equivalent or better efficacy with only about 1 / 10th the dose administered intravenously, significantly clearing Aβ deposits in the brains of AD model mice and improving pathology.

This invention relates to animal models and their applications, specifically to a method for constructing a spontaneous mouse cerebral edema model and its application. This invention utilizes PEN2... fl / + Mice and PEN2 fl / + Mice were mated to obtain PEN2. fl / fl Homozygous mice; then the obtained PEN2 fl / fl Mice and hGFAP Cre / + Mice were mated to obtain PEN2. fl / + hGFAP Cre / + Mice; the final PEN2 obtained fl / + hGFAP Cre / + Mice and PEN2 fl / fl Mice were mated to obtain PEN2. fl / fl hGFAP Cre / + The mouse model is a spontaneous mouse cerebral edema model. In this model, PEN2 protein levels are significantly downregulated, and the mouse exhibits a severe cerebral edema phenotype. This model can be used to establish a cerebral edema drug screening platform. It can also be used for research on cerebral edema-related diseases, such as the pathogenesis of cerebral edema caused by infection, glioma, and traumatic brain injury, as well as for the development of technologies and products for the diagnosis and treatment of related diseases.

The application discloses a kind of mouse brain ischemic lesion automatic quantification method and system based on deep learning, belong to medical image processing and artificial intelligence technical field.The method includes: standardization pretreatment is carried out to T1WI, T2WI, DTI and ASL and other multi-modal MRI data, and enhanced feature tensor is constructed;Lesion intelligent preliminary segmentation is carried out using BA-U-Net network guided by physical prior, and biophysical consistency loss is introduced;Boundary refining is carried out to segmentation result using graph convolution network;Based on LDDMM registration and neural ordinary differential equation model, dynamic evolution modeling is carried out to multi-time point lesion, and severity score is calculated;Finally, comprehensive pathophysiological feature vector is constructed, XGBoost model is used for prediction, and interactive report containing 3D visual model is generated by SHAP explanation.The system includes corresponding functional module.The application realizes high-precision, reproducible automatic quantification to fuzzy lesion, improves the robustness of pathological pattern recognition, and provides dynamic biomarker for drug evaluation.

The invention discloses application of a reagent for detecting an SLC17A7 autoantibody in diagnosis of nervous system diseases. By comparing different fluorescence modes of autoimmune antibodies related to IgG of healthy people in mouse brain tissue slices of patients with nervous system diseases, it is found that fluorescence signals only exist in the patients with nervous system diseases and do not exist in the healthy people, and it is prompted that the patients possibly have the autoimmune antibodies. According to the invention, IgG specific protein related to nervous system diseases is sought through a co-immunoprecipitation technology, a specific SLC17A7 autoantibody is found through cell immunofluorescence (CBA) detection, verification is carried out in cerebrospinal fluid, and finally it is determined that the SLC17A7 autoantibody can be used as a specific marker for diagnosis of nervous system autoimmune diseases. The SLC17A7 is taken as a detection antigen, detection of the expression of the SLC17A7 autoantibody can be applied to a kit for detecting the SLC17A7 autoantibody, the kit can be applied to detection of nervous system diseases, markers for identifying the nervous system diseases are enriched, and the detection accuracy of nervous system related diseases is improved.

The invention discloses a fluorescent / electrochemical dual-mode probe for detecting hydrogen peroxide (H2O2) as well as a preparation method and application of the fluorescent / electrochemical dual-mode probe, and belongs to the technical field of organic probe molecular analysis and detection. The probe takes resorufin (Re) as a fluorescence and electrochemical double-signal report unit and pentafluorobenzenesulfonyl (PS) as an H2O2 response unit, and is named as Re-PS. The preparation process comprises the following steps: under the conditions of nitrogen protection and ice bath, resorufin and pentafluorobenzene sulfonyl chloride react in an anhydrous dichloromethane solvent under the catalysis of triethylamine, and a target product is obtained through rotary evaporation concentration and silica gel column chromatography purification. The probe has both open-type fluorescence detection and ratio-type electrochemical detection functions, and is used for quantitative analysis of H2O2 in Alzheimer's disease (AD) model mouse brain microdialysate. Compared with the existing detection technology, the probe provided by the invention has high stability (37 DEG C, pH 7.4), and the hydrolysis rate lt in 15 min; the method has the advantages of high sensitivity (5%), high selectivity (no obvious response to other active oxygen and biomolecules) and accurate detection (dual-mode signal cross validation and recovery rate of 96.0%-103.0%), provides a reliable tool for accurate detection of H2O2 in biological samples, and has important application value in neurodegenerative disease mechanism research and related diagnosis and treatment evaluation.

This invention proposes a novel fixation device for mouse brain imaging, comprising a first fixation component, an adjustment platform connected to the bottom of the first fixation component, a mounting base plate connected to the bottom of the adjustment platform, and a second fixation component mounted on the mounting base plate, with one end of the second fixation component close to the first fixation component. The first fixation component includes an L-shaped plate mounted on the top of the adjustment platform. Two supporting cylinders are symmetrically arranged on the L-shaped plate near the second fixation component. The top of each supporting cylinder is movably connected to a first connecting plate. A brain fixation plate is connected between the two first connecting plates and fixed to the mouse's head. The brain fixation plate has positioning holes for locating the viewing window area for mouse brain imaging. This device reduces stress response in mice during experiments, improves experimental reliability and repeatability, ensures absolute stability of mice in an awake state, and effectively improves the accuracy of experimental data.

The application provides a construction method and application of a Toxoplasma gondii attenuated strain PruDelta pp2a-c and belongs to the technical field of biological medicine. The TgPP2A-C gene is knocked out to obtain a TgPP2A-C gene deletion Toxoplasma gondii attenuated strain. After the gene is deleted, a large number of starch granules are aggregated between the bodies of the Toxoplasma gondii, and the Toxoplasma gondii loses the ability to form cysts. The in-vitro proliferation speed and pathogenicity of the TgPP2A-C gene deletion Toxoplasma gondii attenuated strain are significantly reduced compared with those of a wild strain. After being infected with the TgPP2A-C gene deletion strain, a mouse does not get ill or die, and no cysts are detected in the brain tissue of the mouse, so the TgPP2A-C gene deletion strain has high safety to a host. After a mouse is immunized with the TgPP2A-C gene deletion Toxoplasma gondii attenuated strain, the antibody level of the mouse is significantly improved, and the mouse can provide significant immunoprotection efficacy against high-dose Toxoplasma gondii RH tachyzoite and Pru cyst re-infection, and can prevent re-infection of Toxoplasma gondii.

The invention discloses an application of circWHSC1 as a biomarker in preparation of a product for diagnosing or treating ineffective recanalization after ischemic stroke. According to the present invention, the circRNA sequencing results show that the expression of the circWHSC1 (including hsacirc0001388 and nucirc0001336) in the ineffective recanalization patient body is significantly reduced, and the circWHSC1 is verified in the mouse brain tissue, the plasma and the thrombus model of the tMCAO model; functional studies show that the circWHSC1 can significantly reduce the cerebral infarction volume of the mouse. The circWHSC1 can be used for early diagnosis, risk assessment, severity judgment, curative effect monitoring and prognosis judgment of invalid recanalization, and can be used as a drug target for screening candidate drugs for preventing or treating invalid recanalization. The invention provides a molecular diagnosis marker and a therapeutic target for invalid recanalization, and has important clinical value.

The invention discloses an NIR-II region fluorescent probe suitable for intrathecal injection, a preparation method of the NIR-II region fluorescent probe and application of the NIR-II region fluorescent probe in cerebrovascular imaging, and belongs to the technical field of probe preparation. The problem of low resolution of current cerebrovascular imaging is solved. The rare earth nano fluorescent material is prepared into the NIR-II region fluorescent probe, delivery of large-size fluorescent imaging particles is achieved through intrathecal injection, and then cerebral vascular imaging is achieved. According to the rare earth nano fluorescent material, NaErF4: x% Ce serves as a fluorescence emission core, NaYF4: y% Yb serves as a fluorescence emission middle layer, NaYF4 serves as a fluorescence emission shell layer, through Er < 3 + > ion self-sensitization, under 808 nm excitation, an NIR-II region fluorescence emission peak of 1525 nm is achieved, NaYF4 serves as an inert shell layer, the luminous intensity of the fluorescent material is further improved, and NIR-II region high-resolution fluorescence imaging of mouse cerebral vessels is achieved in combination with intrathecal injection.

A co-culture model of brain glioma organoids and mouse brain slices, characterized in that the co-culture model is prepared by the following method: (1) taking mouse brain slices, culturing to obtain cultured mouse brain slices; (2) injecting brain glioma organoids into the cultured mouse brain slices obtained in step (1) to obtain brain slices injected with brain glioma organoids; (3) culturing the brain slices injected with brain glioma organoids obtained in step (2) to obtain the co-culture model. The co-culture model of the application can be used to evaluate the invasion phenotype of glioma organoids in vitro and to test and screen brain glioma drugs.

The invention discloses a multifunctional fixing device for mouse ventricular micro-injection and a using method. The multifunctional fixing device comprises an operation table, a height adjusting assembly, a fixing plate, a cranial height adjusting frame, a mounting base, an incisor hook and an ear rod. Wherein the operation table comprises a bottom plate and a vertical plate which are vertically connected, a sinking groove is formed in the bottom plate, and a lifting table is arranged in the groove; the height adjusting assembly is parallel to the vertical plate and close to the bottom plate side; the fixed plate is provided with two symmetrical extension strips at the moving end of the adjusting assembly and on the deviating side, the other surface of the fixed plate is provided with a length adjusting groove, and a first driving piece is arranged in the groove; the cranial height adjusting frame is connected with the first driving piece and provided with a second driving piece. A fixing hole is formed in the far end of the mounting seat; and the incisor hook is arranged on the mounting seat and is positioned above the fixing hole. The two ear rods are symmetrically arranged at the far end of the extension strip. The scheme has the effects of reducing damage to mice, reducing experimental pollution and improving operation stability.

The invention relates to an in vitro method of generating a murine cerebral organoid cell culture model, comprising cultivating murine neural stem cells obtained from an adult mouse until neurospheres have formed, and subsequently differentiating said neurospheres, thereby generating a murine cerebral organoid cell culture model. The invention further relates to an in vitro murine cerebral organoid cell culture model comprising mature astrocytes, oligodendrocytes and / or neurons produced according to the method of the invention and its use for drug or toxicity screenings or for studying neurological diseases. In other aspects the invention further relates to kits, cell culture media and supplement compositions comprising components to be used in the context of the present invention.

The application provides an animal brain metabolite identification method based on mass spectrometry imaging technology and application, and establishes a mouse brain tissue slice endogenous metabolite DESI-MSI analysis method based on mass spectrometry imaging technology, which comprises the following steps: after preparing metabolite control sample imaging samples and brain tissue slice imaging samples, multiple animal brain tissues are attached to the same glass slide, mass spectrometry imaging condition optimization is carried out by using the control sample imaging samples, and mass spectrometry imaging analysis is carried out by using the brain tissue slice imaging samples; the image of the biological sample is divided into multiple structure regions in combination with tissue morphological characteristics; for the structure regions, multivariate statistical analysis is carried out to obtain different metabolites in different structure regions; metabolite identification is carried out based on parent ions and characteristic daughter ion profiles; and the method is used for disease mechanism research and drug intervention effect evaluation on diseases.

The application belongs to the technical field of animal model construction, and discloses a method for establishing a tumor-bearing animal model for an OCT system, wherein a SD rat supratentorial brain parenchymal glioma model, a SD rat chiasma glioma model and a SD rat brain stem glioma model are constructed by using a C6 cell line; a rat sciatic nerve sheath tumor model and a rat trigeminal nerve RT4 tumor model are constructed by using an RT4 cell line to obtain a SD rat RT4 tumor cell animal model; and a BALB / c nude mouse U87MG tumor cell animal model and a BALB / c nude mouse IOMM-Lee tumor cell animal model are constructed by using a U87MG cell line and an IOMM-Lee cell line, respectively. The application successfully constructs a rat brain glioma model, a chiasma glioma model, a trigeminal nerve sheath tumor model, a sciatic nerve sheath tumor model, a nude mouse brain glioma model and a nude mouse sciatic nerve meningioma model.

The invention discloses a dual-targeting viscosity detection near-infrared fluorescence / photoacoustic probe as well as preparation and application thereof, and a probe ER-V2 with viscosity specific recognition capability is successfully designed and synthesized by taking trimethylbenzoindole as a core. The probe ER-V2 is based on a hemicyanine donor-pi-receptor (D-pi-A) structure, a p-toluene sulfonamide part is used for targeting endoplasmic reticulum, and an N, N-dimethylaminophenyl part is used for A beta plaque binding, so that precise double targeting is realized. The extended pi conjugation provides near-infrared emission, enhances viscosity sensitivity by limiting intramolecular rotation, and produces a strong photoacoustic signal. In combination with high sensitivity of near-infrared fluorescence and strong penetrating power of a photoacoustic technology in tissues, the probe ER-V2 can penetrate a blood brain barrier, realizes real-time and high-sensitivity near-infrared fluorescence / photoacoustic imaging in neuroglial cells and the brain of a mouse with the Alzheimer's disease, and has important significance on early diagnosis of the Alzheimer's disease. The fluorescent probe is expected to become a useful fluorescent tool for researching Alzheimer's disease and endoplasmic reticulum related diseases in the future.

The application discloses application of a composition in a synergist of a medicine for treating depression, wherein the composition is made of Rubia cordifolia, Taxillus delavayi, Pyrrosia lingua, Oldenlandia diffusa and Achyranthes bidentata, and the medicine for treating depression is made of Astragalus membranaceus, Atractylodes macrocephala, Poria cocos, Codonopsis pilosula, prepared Aconitum (black smooth tablet), Cornus officinalis, Salvia miltiorrhiza and Motherwort. The medicine combination prepared from the composition and the medicine for treating depression can significantly improve the depressive behavior of a depressive mouse, relieve the symptom of interest deficiency, and increase the content of a neurotransmitter in the brain of the depressive mouse. Further clinical tests find that the medicine combination has a significant clinical curative effect on various Chinese medical syndrome types of depression, such as liver depression and qi stagnation type, liver depression and fire type, liver depression and spleen deficiency type, phlegm and qi stagnation type, heart and spleen deficiency type, and kidney deficiency and liver depression type, and shows a good anti-depression effect, so the medicine combination has a wide application prospect.

The application discloses application of an S1PR1 selective agonist SAR247799 in preparation of a drug for treating neuromyelitis optica spectrum disorders. The SAR247799 can up-regulate S1PR1 expression of astrocytes, activate an S1PR1 signal path of the astrocytes, inhibit AQP4-IgG and complement-mediated damage of the astrocytes, reduce loss of AQP4, GFAP and ALDH1L1 in a lesion area of brain tissue of a neuromyelitis optica spectrum disorder model mouse, and relieve pathological damage of the neuromyelitis optica spectrum disorder model. In-vivo and in-vitro experiments prove that the SAR247799 can effectively inhibit AQP4-IgG and complement-dependent cytotoxicity effects and promote survival of the astrocytes. The application provides a novel, efficient and specific targeted drug for clinical treatment of the neuromyelitis optica spectrum disorder.

This invention belongs to the field of organic probe molecular analysis and detection technology, and discloses a fluorescence / electrochemical dual-mode probe for detecting copper ions (Cu2+), its preparation method, and its application. The probe's molecular structure is as follows: Under argon protection and an ice-salt bath, halogenated hydroxyl chloride and pyridinecarboxyl chloride hydrochloride undergo an esterification reaction in anhydrous dichloromethane solvent catalyzed by triethylamine. The target product is obtained after extraction, drying, vacuum concentration, and column chromatography purification. This probe combines "on-screen" fluorescence detection with ratiometric electrochemical detection, enabling highly sensitive and selective quantitative analysis of free Cu2+ in complex biological samples such as dialysis fluid from Alzheimer's disease (AD) model mice. Compared to existing detection technologies, this probe has advantages such as high selectivity, low detection limit, good stability, and accurate dual-signal cross-validation results, providing a reliable tool for the accurate detection of Cu2+ in biological samples.

The invention relates to a near-infrared band ratio type rare earth fluorescent nanoprobe as well as a preparation method and application thereof. The ratio-type rare earth fluorescent probe is a nanocrystal with a core-shell structure, an inner core layer of the ratio-type rare earth fluorescent probe is a light-emitting layer which absorbs laser radiation and emits a near-infrared fluorescent wave band, a middle shell layer of the ratio-type rare earth fluorescent probe is a light-emitting shell layer which absorbs laser radiation and emits another near-infrared fluorescent wave band, and an outer shell layer of the ratio-type rare earth fluorescent probe is an inert shell layer. Wherein the inner core layer takes Tm < 3 + > as a light-emitting center, and the light-emitting shell layer takes Er < 3 + > as a light-emitting center. Through difference response of two fluorescence signal wave bands to water absorption, an index relation between ratio-type fluorescence signal intensity and tissue penetration depth is established, and noninvasive depth positioning and imaging of a mouse living body are realized. The fluorescent nanoprobe can be used for depth positioning of blood vessels of the brain, the abdomen and the legs of a mouse and continuous monitoring of a dynamic migration process from the blood vessels to bones, and has a wide application prospect in the aspect of in-vivo ratio depth imaging.

The present invention belongs to the technical field of mouse brain slice image processing, and specifically discloses a method for scoring the severity of cerebral infarction based on TTC staining of brain slices in a mouse cerebral infarction model. The method comprises: establishing a mouse cerebral infarction model; euthanizing the mouse, dissecting the mouse brain, and then performing TTC staining on the slices; acquiring brain slice images using a scanner; and then performing image algorithm processing on the brain slice images to quickly and accurately assess the degree of cerebral infarction. At the same time, the degree of damage to the ischemic penumbra (i.e., TTC staining saturation) is incorporated as a quantitative indicator to improve consistency with the neurobehavioral performance of the mouse.